Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, PD and Safety of TG103 Injection by Two Manufacturing Processes in Healthy Chinese Males
NCT04839744Phase 1Completed
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- May 2021
- Primary completion
- Jun 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GX-G6 in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by CSPC Baike Biopharmaceutical. Primary endpoints: Peak Plasma Concentration at Day 28 and Area under the plasma concentration versus time curve at Day 28. Started May 2021; status: completed.
02
Drugs
GX-G6
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04839744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839744.